Reports Q1 revenue $10M, consensus $1.67M. “We are pleased with the continued momentum of our obexelimab program across ongoing Phase 2 and Phase 3 clinical trials, for which we expect to report topline results later this year from trials in patients with relapsing multiple sclerosis and IgG4-RD,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. “With a strengthened team following the recent additions of Lisa and Haley, we are well positioned to execute on our clinical trials and advance obexelimab as a differentiated B cell inhibitor with a potentially safer, more potent and convenient profile for patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before June 16, 2025 to Discuss Your Rights – ZBIO
- Zenas BioPharma appoints Haley Laken as CSO
- Wedbush bullish on Zenas BioPharma, initiates with an Outperform
- Zenas BioPharma initiated with an Outperform at Wedbush
- Zenas BioPharma appoints Lisa von Moltke as Head of R&D, CMO